Outcome Measures in Polymyalgia Rheumatica. A Systematic Review

REFERENCES

1. 1.↵
   1. Crowson CS,
   2. Matteson EL,
   3. Myasoedova E,
   4. Michet CJ,
   5. Ernste FC,
   6. Warrington KJ,
   7. et al.

   The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011;63:633–9.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Hoes JN,
   2. Jacobs JW,
   3. Boers M,
   4. Boumpas D,
   5. Buttgereit F,
   6. Caeyers N,
   7. et al.

   EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560–7.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Binard A,
   2. De Bandt M,
   3. Berthelot JM,
   4. Saraux A

   . Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios. Arthritis Rheum 2007;57:481–6.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Leeb BF,
   2. Bird HA,
   3. Nesher G,
   4. Andel I,
   5. Hueber W,
   6. Logar D,
   7. et al.

   EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Ann Rheum Dis 2003;62:1189–94.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Dejaco C,
   2. Duftner C,
   3. Cimmino MA,
   4. Dasgupta B,
   5. Salvarani C,
   6. Crowson CS,
   7. et al.

   Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis 2011;70:447–53.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Leeb BF,
   2. Bird HA

   . A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 2004;63:1279–83.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Kirwan JR,
   2. Boers M,
   3. Tugwell P

   . Updating the OMERACT filter at OMERACT 11. J Rheumatol 2014;41:975–7.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Kirwan JR,
   2. Boers M,
   3. Hewlett S,
   4. Beaton D,
   5. Bingham CO 3rd,
   6. Choy E,
   7. et al.

   Updating the OMERACT filter: core areas as a basis for defining core outcome sets. J Rheumatol 2014;41:994–9.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Boers M,
   2. Kirwan JR,
   3. Tugwell P,
   4. Beaton D,
   5. Bingham CO 3rd,
   6. Conaghan PG,
   7. et al.

   The OMERACT handbook. [Internet. Accessed March 3, 2015.] Available from: www.omeract.org/pdf/OMERACT_Handbook.pdf
10. 10.↵
    1. Boers M,
    2. Kirwan JR,
    3. Wells G,
    4. Beaton D,
    5. Gossec L,
    6. d’Agostino MA,
    7. et al.

    Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67:745–53.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Boers M,
    2. Kirwan JR,
    3. Gossec L,
    4. Conaghan PG,
    5. D’Agostino MA,
    6. Bingham CO,
    7. et al.

    How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0. J Rheumatol 2014;41:1025–30.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Lund B,
    2. Egsmose C,
    3. Jorgensen S,
    4. Krogsgaard MR

    . Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica. Calcif Tissue Int 1987;41:316–20.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Littman BH,
    2. Bjarnason D,
    3. Bryant G,
    4. Engelbrecht J,
    5. Cohen M,
    6. Mertz L,
    7. et al.

    Steroid sparing activity of tenidap in patients with polymyalgia rheumatica: a multicenter double blind randomized placebo controlled study. J Rheumatol 1995;22:1097–103.

    OpenUrlPubMed
14. 14.↵
    1. Krogsgaard MR,
    2. Lund B,
    3. Johnsson B

    . A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheumatol 1995;22:1660–2.

    OpenUrlPubMed
15. 15.↵
    1. Di Munno O,
    2. Imbimbo B,
    3. Mazzantini M,
    4. Milani S,
    5. Occhipinti G,
    6. Pasero G

    . Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. J Rheumatol 1995;22:1492–8.

    OpenUrlPubMed
16. 16.↵
    1. Krogsgaard MR,
    2. Thamsborg G,
    3. Lund B

    . Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. Ann Rheum Dis 1996;55:143–6.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Ferraccioli G,
    2. Salaffi F,
    3. De Vita S,
    4. Casatta L,
    5. Bartoli E

    . Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996;23:624–8.

    OpenUrlPubMed
18. 18.↵
    1. Dasgupta B,
    2. Dolan AL,
    3. Panayi GS,
    4. Fernandes L

    . An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998;37:189–95.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Salvarani C,
    2. Cantini F,
    3. Olivieri I,
    4. Barozzi L,
    5. Macchioni L,
    6. Boiardi L,
    7. et al.

    Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol 2000;27:1470–6.

    OpenUrlPubMed
20. 20.↵
    1. Caporali R,
    2. Cimmino MA,
    3. Ferraccioli G,
    4. Gerli R,
    5. Klersy C,
    6. Salvarani C,
    7. et al.

    Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;141:493–500.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Salvarani C,
    2. Macchioni P,
    3. Manzini C,
    4. Paolazzi G,
    5. Trotta A,
    6. Manganelli P,
    7. et al.

    Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007;146:631–9.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Kreiner F,
    2. Galbo H

    . Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther 2010;12:R176.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Bjorkman MP,
    2. Pilvi TK,
    3. Kekkonen RA,
    4. Korpela R,
    5. Tilvis RS

    . Similar effects of leucine rich and regular dairy products on muscle mass and functions of older polymyalgia rheumatica patients: a randomized crossover trial. J Nutr Health Aging 2011;15:462–7.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Salvarani C,
    2. Cantini F,
    3. Niccoli L,
    4. Catanoso MG,
    5. Macchioni P,
    6. Pulsatelli L,
    7. et al.

    Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 2003;30:760–3.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Catanoso MG,
    2. Macchioni P,
    3. Boiardi L,
    4. Pipitone N,
    5. Salvarani C

    . Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum 2007;57:1514–9.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Cimmino MA,
    2. Parodi M,
    3. Montecucco C,
    4. Caporali R

    . The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. BMC Musculoskelet Disord 2011;12:94.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Weyand CM,
    2. Fulbright JW,
    3. Evans JM,
    4. Hunder GG,
    5. Goronzy JJ

    . Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999;159:577–84.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Cantini F,
    2. Salvarani C,
    3. Olivieri I,
    4. Macchioni L,
    5. Ranzi A,
    6. Niccoli L,
    7. et al.

    Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000;30:17–24.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Myklebust G,
    2. Wilsgaard T,
    3. Jacobsen BK,
    4. Gran JT

    . Causes of death in polymyalgia rheumatica. A prospective longitudinal study of 315 cases and matched population controls. Scand J Rheumatol 2003;32:38–41.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Salvarani C,
    2. Cantini F,
    3. Niccoli L,
    4. Macchioni P,
    5. Consonni D,
    6. Bajocchi G,
    7. et al.

    Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005;53:33–8.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Boiardi L,
    2. Casali B,
    3. Farnetti E,
    4. Pipitone N,
    5. Nicoli D,
    6. Cantini F,
    7. et al.

    Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol 2006;33:703–8.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Kremers HM,
    2. Reinalda MS,
    3. Crowson CS,
    4. Davis JM 3rd,
    5. Hunder GG,
    6. Gabriel SE

    . Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 2007;57:279–86.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Leeb BF,
    2. Rintelen B,
    3. Sautner J,
    4. Fassl C,
    5. Bird HA

    . The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum 2007;57:810–5.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Hutchings A,
    2. Hollywood J,
    3. Lamping DL,
    4. Pease CT,
    5. Chakravarty K,
    6. Silverman B,
    7. et al.

    Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 2007;57:803–9.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Binard A,
    2. de Bandt M,
    3. Berthelot JM,
    4. Saraux A

    . Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum 2008;59:263–9.

    OpenUrlCrossRefPubMed
36. 36.↵
    1. Cimmino MA,
    2. Salvarani C,
    3. Macchioni P,
    4. Gerli R,
    5. Bartoloni Bocci E,
    6. Montecucco C,
    7. et al.

    Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheumatol 2008;26:395–400.

    OpenUrlPubMed
37. 37.↵
    1. Pulsatelli L,
    2. Boiardi L,
    3. Pignotti E,
    4. Dolzani P,
    5. Silvestri T,
    6. Macchioni P,
    7. et al.

    Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk. Arthritis Rheum 2008;59:1147–54.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Macchioni P,
    2. Catanoso MG,
    3. Pipitone N,
    4. Boiardi L,
    5. Salvarani C

    . Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology (Oxford) 2009;48:1566–9.

    OpenUrlAbstract/FREE Full Text
39. 39.↵
    1. Calvo L,
    2. Pistone G,
    3. Arnone S,
    4. Colomba D,
    5. Amico S,
    6. Giacalone A,
    7. et al.

    Polymyalgia rheumatica and vertebral fractures: a 1-year pilot controlled study. Rheumatol Int 2010;30:1245–7.

    OpenUrlCrossRefPubMed
40. 40.↵
    1. Jiménez-Palop M,
    2. Naredo E,
    3. Humbrado L,
    4. Medina J,
    5. Uson J,
    6. Francisco F,
    7. et al.

    Ultrasonographic monitoring of response to therapy in polymyalgia rheumatica. Ann Rheum Dis 2010;69:879–82.

    OpenUrlAbstract/FREE Full Text
41. 41.↵
    1. Kang JH,
    2. Sheu JJ,
    3. Lin HC

    . Polymyalgia rheumatica and the risk of stroke: a three-year follow-up study. Cerebrovasc Dis 2011;32:497–503.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Mazzantini M,
    2. Torre C,
    3. Miccoli M,
    4. Baggiani A,
    5. Talarico R,
    6. Bombardieri S,
    7. et al.

    Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol 2012;39:552–7.

    OpenUrlAbstract/FREE Full Text
43. 43.↵
    1. Cleuziou C,
    2. Binard A,
    3. De Bandt M,
    4. Berthelot JM,
    5. Saraux A

    . Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice. J Rheumatol 2012;39:310–3.

    OpenUrlAbstract/FREE Full Text
44. 44.↵
    1. Matteson EL,
    2. Maradit-Kremers H,
    3. Cimmino MA,
    4. Schmidt WA,
    5. Schirmer M,
    6. Salvarani C,
    7. et al.

    Patient-reported outcomes in polymyalgia rheumatica. J Rheumatol 2012;39:795–803.

    OpenUrlAbstract/FREE Full Text
45. 45.↵
    1. McCarthy EM,
    2. MacMullan PA,
    3. Al-Mudhaffer S,
    4. Madigan A,
    5. Donnelly S,
    6. McCarthy CJ,
    7. et al.

    Plasma fibrinogen is an accurate marker of disease activity in patients with polymyalgia rheumatica. Rheumatology (Oxford) 2013;52:465–71.

    OpenUrlAbstract/FREE Full Text
46. 46.↵
    1. McCarthy EM,
    2. MacMullan PA,
    3. Al-Mudhaffer S,
    4. Madigan A,
    5. Donnelly S,
    6. McCarthy CJ,
    7. et al.

    Plasma fibrinogen along with patient-reported outcome measures enhances management of polymyalgia rheumatica: a prospective study. J Rheumatol 2014;41:931–7.

    OpenUrlAbstract/FREE Full Text
47. 47.↵
    1. Chuang TY,
    2. Hunder GG,
    3. Ilstrup DM,
    4. Kurland LT

    . Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982;97:672–80.

    OpenUrlCrossRefPubMed
48. 48.↵
    1. Bird HA,
    2. Esselinckx W,
    3. Dixon AS,
    4. Mowat AG,
    5. Wood PH

    . An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979;38:434–9.

    OpenUrlAbstract/FREE Full Text
49. 49.↵
    1. Healey LA

    . Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984;13:322–8.

    OpenUrlCrossRefPubMed
50. 50.↵
    1. Jones JG,
    2. Hazleman BL

    . Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981;40:1–5.

    OpenUrlAbstract/FREE Full Text
51. 51.↵
    1. Wolfe F

    . A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000;43:2751–61.

    OpenUrlCrossRefPubMed
52. 52.↵
    1. Jenkinson C,
    2. Stewart-Brown S,
    3. Petersen S,
    4. Paice C

    . Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health 1999;53:46–50.

    OpenUrlAbstract
53. 53.↵
    1. Binard A,
    2. Lefebvre B,
    3. De Bandt M,
    4. Berthelot JM,
    5. Saraux A

    . Validity of the polymyalgia rheumatica activity score in primary care practice. Ann Rheum Dis 2009;68:541–5.

    OpenUrlAbstract/FREE Full Text
54. 54.↵
    1. Mackie SL,
    2. Arat S,
    3. da Silva J,
    4. Duarte C,
    5. Halliday S,
    6. Hughes R,
    7. et al.

    Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR. J Rheumatol 2014;41:819–23.

    OpenUrlAbstract/FREE Full Text
55. 55.↵
    1. Kwoh CK,
    2. O’Connor GT,
    3. Regan-Smith MG,
    4. Olmstead EM,
    5. Brown LA,
    6. Burnett JB,
    7. et al.

    Concordance between clinician and patient assessment of physical and mental health status. J Rheumatol 1992;19:1031–7.

    OpenUrlPubMed
56. 56.↵
    1. Neville C,
    2. Clarke AE,
    3. Joseph L,
    4. Belisle P,
    5. Ferland D,
    6. Fortin PR

    . Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. J Rheumatol 2000;27:675–9.

    OpenUrlPubMed
57. 57.↵
    1. Hidding A,
    2. van Santen M,
    3. De Klerk E,
    4. Gielen X,
    5. Boers M,
    6. Geenen R,
    7. et al.

    Comparison between self-report measures and clinical observations of functional disability in ankylosing spondylitis, rheumatoid arthritis and fibromyalgia. J Rheumatol 1994;21:818–23.

    OpenUrlPubMed